文献速递血管炎类风湿关节炎其他结缔组织病

风湿科实践中糖皮质激素毒性的前瞻性评估:聚焦糖皮质激素毒性指数

Prospective assessment of glucocorticoid toxicity in rheumatology practice: a focus on the glucocorticoid toxicity index.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项前瞻性研究在风湿科门诊纳入156例新用或使用糖皮质激素≤2年的炎症性关节炎、结缔组织病和血管炎患者,用糖皮质激素毒性指数(GTI)评估6个月内的糖皮质激素毒性。结果显示累积糖皮质激素剂量越高GTI评分越高,新用药组中血管炎患者GTI评分高于炎症性关节炎患者。

要点

  • 累积糖皮质激素剂量越高,GTI评分越高(P < 0.001)。
  • 新用药组中血管炎患者GTI评分高于炎症性关节炎患者(P < 0.001)。
  • 新用药组第6个月GTI-CWS较第3个月显著升高。

核心结论

  • GTI评分与累积糖皮质激素剂量相关,新用药的血管炎患者GTI评分高于炎症性关节炎患者。
  • GTI可用于个体化评估和管理患者因糖皮质激素治疗出现的不良反应。

研究设计与样本

  • 前瞻性研究,纳入156例患者(48.7%为新用药者),平均年龄49.1 ± 17.1岁。
  • 纳入新处方糖皮质激素或持续使用糖皮质激素≤2年的炎症性关节炎、结缔组织病和血管炎患者。
  • 在基线、第3个月和第6个月记录GTI-AIS、GTI-CWS和累积糖皮质激素剂量,采用广义估计方程(GEE)评估GTI评分及相关因素。

主要发现

  • 两组中较高的累积糖皮质激素剂量均与较高的GTI评分相关(P < 0.001)。
  • 新用药组中血管炎患者GTI评分高于炎症性关节炎患者(P < 0.001)。
  • 新用药组第6个月GTI-CWS较第3个月显著升高。
  • 有用药经验组第3个月和第6个月GTI-AIS与GTI-CWS差异有统计学意义(P < 0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The glucocorticoid toxicity index (GTI) is developed to measure glucocorticoid (GC)-related morbidity over time. This study aimed to assess GC-toxicity in patients at a rheumatology outpatient clinic by using the GTI and to identify the factors that interfere with the GTI. METHODS: This prospective study included patients with inflammatory arthritis (IA), connective tissue disease and vasculitis who were newly prescribed GC-treatment (GC-naive) or have been still on GC-treatment for ≤2 years (GC-experienced). Patient demographics and disease characteristics, aggregate improvement score (GTI-AIS), cumulative worsening score (GTI-CWS) and cumulative GC-doses were recorded at baseline, 3rd month and 6th month. Generalized estimating equations (GEE) were used to evaluate the GTI scores and associated factors including cumulative GC-doses. RESULTS: The study included 156 (48.7% GC-naive) patients with a mean age of 49.1 ± 17.1 years. More than half of the patients in both groups had a diagnosis of vasculitis. A higher cumulative GC-dose was found to be associated with higher GTI-scores in both groups (P < 0.001). In the GC-naive group, patients with vasculitis showed higher GTI-scores than IA patients (P < 0.001); there was also a significant increase in the GTI-CWS at the 6th month compared with the 3rd month. In the GC-experienced group, GTI-AIS and GTI-CWS were significantly different at 3rd and 6th month (P < 0.05). CONCLUSION: It was shown that GTI scores were associated with cumulative GC-doses and vasculitis patients in the GC-naive patients had higher GTI scores than inflammatory arthritis. The GTI allows individualized assessment and management of adverse effects experienced by patients as a result of GC treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bahap-Kara M, Sariyildiz E, Zengin HY, et al. Prospective assessment of glucocorticoid toxicity in rheumatology practice: a focus on the glucocorticoid toxicity index. Rheumatology (Oxford). 2025. PMID: 38781534. doi:10.1093/rheumatology/keae288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。